Sage Bounces Back, Eyes FDA Filing for Postpartum Drug

07:45 EST 9 Nov 2017 | Xconomy

There may be a new treatment on the horizon for postpartum depression, an often severe form of depression that affects women after childbirth. Sage Therapeutics reported this morning that an experimental neurological drug known as brexanolone succeeded in two Phase 3 trials, setting the stage for an FDA approval filing next year. Cambridge, MA-based Sage […]

Original Article: Sage Bounces Back, Eyes FDA Filing for Postpartum Drug


More From BioPortfolio on "Sage Bounces Back, Eyes FDA Filing for Postpartum Drug"

Quick Search


Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Mental Health
Adhd Anorexia Depression Dyslexia Mental Health Psychiatry Schizophrenia Stress Mental health, although not being as obvious as physical health, is very important, causing great unhappiness to those affected, causing add...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...